The sequencing of the human genome and the identification of links
between specific genetic variants and diseases have led to
tremendous excitement over the potential of genomics to direct
patient treatment toward more effective or less harmful
interventions. Still, the use of whole genome sequencing challenges
the traditional model of medical care where a test is ordered only
when there is a clear indication for its use and a path for
downstream clinical action is known. This has created a tension
between experts who contend that using this information is
premature and those who believe that having such information will
empower health care providers and patients to make proactive
decisions regarding lifestyle and treatment options. In addition,
some stakeholders are concerned that genomic technologies will add
costs to the health care system without providing commensurate
benefits, and others think that health care costs could be reduced
by identifying unnecessary or ineffective treatments. Economic
models are frequently used to anticipate the costs and benefits of
new health care technologies, policies, and regulations. Economic
studies also have been used to examine much more specific issues,
such as comparing the outcomes and cost effectiveness of two
different drug treatments for the same condition. These kinds of
analyses offer more than just predictions of future health care
costs. They provide information that is valuable when implementing
and using new technologies. Unfortunately, however, these economic
assessments are often limited by a lack of data on which to base
the examination. This particularly affects health economics, which
includes many factors for which current methods are inadequate for
assessing, such as personal utility, social utility, and patient
preference. To understand better the health economic issues that
may arise in the course of integrating genomic data into health
care, the Roundtable on Translating Genomic-Based Research for
Health hosted a workshop in Washington, DC, on July 17-18, 2012,
that brought together economists, regulators, payers, biomedical
researchers, patients, providers, and other stakeholders to discuss
the many factors that may influence this implementation. The
workshop was one of a series that the roundtable has held on this
topic, but it was the first focused specifically on economic
issues. The Economics of Genomic Medicine summarizes this workshop.
Table of Contents Front Matter 1 Introduction and Overview 2
Genomics, Population Health, and Technology 3 The Intersection of
Genomics and Health Economics 4 Preconception Care and Sequencing 5
Unprovoked Deep Vein Thrombosis 6 Cancer Care 7 Panelists' and
Stakeholders' Perspectives References Appendix A: Workshop Agenda
Appendix B: Speaker Biographical Sketches Appendix C: Statement of
Task Appendix D: Registered Attendees
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!